三阴性乳腺癌精准分层治疗进展
Advances in Precision Stratified Therapy for Triple-Negative Breast Cancer
DOI: 10.12677/acm.2026.1641748, PDF,   
作者: 钟明亮：内蒙古医科大学第一临床医学院，内蒙古 呼和浩特；张 剑*：内蒙古医科大学附属医院放射治疗科，内蒙古 呼和浩特
关键词: 三阴性乳腺癌；精准治疗；免疫治疗；PARP抑制剂；抗体偶联药物；放疗；Triple-Negative Breast Cancer； Precision Therapy； Immunotherapy； PARP Inhibitor； Antibody-Drug Conjugate； Radiotherapy
摘要: 三阴性乳腺癌(TNBC)是乳腺癌中预后最差、治疗手段最有限的亚型之一，其治疗进展是学术界和临床关注的热点。该综述系统性地整合了近年来在免疫治疗、PARP抑制剂和ADC等领域的突破性研究成果，为临床医生提供了关于TNBC精准治疗现状的全面、及时的图景。
Abstract: Triple-Negative Breast Cancer (TNBC) is one of the breast cancer subtypes with the poorest prognosis and the most limited treatment options, making therapeutic advancements a key focus of both academic research and clinical practice. This review systematically integrates breakthrough research findings in recent years across areas such as immunotherapy, PARP inhibitors, and Antibody-Drug Conjugates (ADCs), providing clinicians with a comprehensive and timely overview of the current landscape of precision therapy for TNBC.
文章引用：钟明亮, 张剑. 三阴性乳腺癌精准分层治疗进展[J]. 临床医学进展, 2026, 16(4): 4762-4772. https://doi.org/10.12677/acm.2026.1641748

参考文献

[1] Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E. and Gianni, L. (2016) Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nature Reviews Clinical Oncology, 13, 674-690. [Google Scholar] [CrossRef] [PubMed]
[2] Jiang, Y., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5. [Google Scholar] [CrossRef] [PubMed]
[3] Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 382, 810-821. [Google Scholar] [CrossRef] [PubMed]
[4] Tutt, A.N.J., Garber, J.E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., et al. (2021) Adjuvant Olaparib for Patients with Brca1-or Brca2-Mutated Breast Cancer. New England Journal of Medicine, 384, 2394-2405. [Google Scholar] [CrossRef] [PubMed]
[5] Cortes, J., Cescon, D.W., Rugo, H.S., Nowecki, Z., Im, S., Yusof, M.M., et al. (2020) Pembrolizumab Plus Chemotherapy versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial. The Lancet, 396, 1817-1828. [Google Scholar] [CrossRef] [PubMed]
[6] Robson, M., Im, S., Senkus, E., Xu, B., Domchek, S.M., Masuda, N., et al. (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 377, 523-533. [Google Scholar] [CrossRef] [PubMed]
[7] Bardia, A., Hurvitz, S.A., Tolaney, S.M., Loirat, D., Punie, K., Oliveira, M., et al. (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 384, 1529-1541. [Google Scholar] [CrossRef] [PubMed]
[8] Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387, 9-20. [Google Scholar] [CrossRef] [PubMed]
[9] Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International Tils Working Group 2014. Annals of Oncology, 26, 259-271. [Google Scholar] [CrossRef] [PubMed]
[10] Radovich, M., Jiang, G., Hancock, B.A., Chitambar, C., Nanda, R., Falkson, C., et al. (2020) Association of Circulating Tumor DNA and Circulating Tumor Cells after Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncology, 6, 1410-1415. [Google Scholar] [CrossRef] [PubMed]
[11] Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9, 176-198. [Google Scholar] [CrossRef] [PubMed]
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2023 [M]. 北京: 人民卫生出版社, 2023.
[13] Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. (2011) Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. [Google Scholar] [CrossRef] [PubMed]
[14] Cortes, J., Rugo, H.S., Cescon, D.W., et al. (2022) Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer: Final Overall Survival Analysis of Keynote-355. The Lancet, 400, 1817-1828.
[15] Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 379, 2108-2121. [Google Scholar] [CrossRef] [PubMed]
[16] Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P.A., Lacroix-Triki, M., et al. (2019) Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 37, 559-569. [Google Scholar] [CrossRef] [PubMed]
[17] Lord, C.J. and Ashworth, A. (2016) BRCAness Revisited. Nature Reviews Cancer, 16, 110-120. [Google Scholar] [CrossRef] [PubMed]
[18] Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R.J., et al. (2019) Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncology, 5, 1473-1478. [Google Scholar] [CrossRef] [PubMed]
[19] Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. [Google Scholar] [CrossRef] [PubMed]
[20] Sikov, W.M., Berry, D.A., Perou, C.M., et al. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33, 13-21.
[21] Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., et al. (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine, 391, 1981-1991. [Google Scholar] [CrossRef] [PubMed]
[22] Geyer, C.E., Garber, J.E., Gelber, R.D., Yothers, G., Taboada, M., Ross, L., et al. (2022) Overall Survival in the Olympia Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1/2 and High-Risk, Early Breast Cancer. Annals of Oncology, 33, 1250-1268. [Google Scholar] [CrossRef] [PubMed]
[23] Masuda, N., Lee, S., Ohtani, S., Im, Y., Lee, E., Yokota, I., et al. (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine, 376, 2147-2159. [Google Scholar] [CrossRef] [PubMed]
[24] Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., et al. (2007) Measurement of Residual Breast Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 25, 4414-4422. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, Y., Wang, H., Yao, H., Li, C., Fang, J. and Xu, J. (2018) Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Frontiers in Pharmacology, 9, Article ID: 536. [Google Scholar] [CrossRef] [PubMed]
[26] Litton, J.K., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Lee, K., et al. (2018) Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine, 379, 753-763. [Google Scholar] [CrossRef] [PubMed]
[27] Tolaney, S.M., Bardia, A., Marmé, F., et al. (2024) Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer: Primary Results from the Phase III ASCENT-03 Study. Annals of Oncology, 35, S1150-S1151.
[28] Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A.M., Nemsadze, G., et al. (2020) Capivasertib Plus Paclitaxel versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38, 423-433. [Google Scholar] [CrossRef] [PubMed]
[29] Mamounas, E.P., Anderson, S.J., Dignam, J.J., Bear, H.D., Julian, T.B., Geyer, C.E., et al. (2012) Predictors of Locoregional Recurrence after Neoadjuvant Chemotherapy: Results from Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology, 30, 3960-3966. [Google Scholar] [CrossRef] [PubMed]
[30] Voorwerk, L., Slagter, M., Horlings, H.M., Sikorska, K., van de Vijver, K.K., de Maaker, M., et al. (2019) Immune Induction Strategies in Metastatic Triple-Negative Breast Cancer to Enhance the Sensitivity to PD-1 Blockade: The TONIC Trial. Nature Medicine, 25, 920-928. [Google Scholar] [CrossRef] [PubMed]
[31] Demaria, S., Romano, E., Brackstone, M. and Formenti, S.C. (2019) Immune Induction Strategies to Enhance Responses to PD-1 Blockade: Lessons from the TONIC Trial. Journal for ImmunoTherapy of Cancer, 7, Article No. 318. [Google Scholar] [CrossRef] [PubMed]
[32] Loap, P., Laki, F., Loria, T., et al. (2021) Concurrent PARP Inhibitors and Radiotherapy in Breast Cancer: From Biology to Clinical Translation. Cancer Treatment Reviews, 99, Article 102246.
[33] White, J.R. and Bellon, J.R. (2020) Precision Radiation Therapy for Breast Cancer. Journal of Clinical Oncology, 38, 2309-2317.

为你推荐